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Summary
Objective: To test the hypothesis that glucose intolerance does not occur when healthy adults consume normal, recommended dosages of
glucosamine sulfate.
Methods: Healthy adults (N=19) ingested 1500 mg of glucosamine sulfate or placebo (double blind) each day for 12 weeks. Three-hour oral
glucose tolerance tests (OGTT) were performed using 75 g of dextrose. These occurred before the start of supplementation, at 6 weeks, and
at the completion of supplementation (12 weeks).
Results: There were no significant differences between fasted levels of serum insulin or blood glucose. Glucosamine sulfate supplementation
did not alter serum insulin or plasma glucose during the OGTT. There were no significant differences within or between treatments, ages or
gender. Glycated hemoglobin measurements at the three time points showed no significant change over time, within or between treatments,
ages or gender. The lack of significant changes may have been due to large standard deviations in the data.
Conclusion: The data suggests that glucosamine supplementation, with normal recommended dosages, does not cause glucose intolerance
in healthy adults. This cannot be determined conclusively, however, until further studies are conducted using alternative types of testing.
© 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Gluosamine sulphate is a widely consumed dietary supple-
ment, particularly by osteoarthritic patients. Over three
million Canadians use glucosamine1,2. Countless studies
have shown glucosamine’s effectiveness in alleviating
osteoarthritis related joint pain3. However, there has been
documented use of glucosamine for general joint pain4.
This is of potential concern as some research suggests
that glucosamine supplementation may cause glucose
intolerance and potentially insulin resistance5–8.
Glucosamine is an amino-polysaccharide, metabolized
by the hexosamine pathway. Both glucose and glucosa-
mine enter the hexosamine-biosynthetic pathway as
glucosamine-6-phosphate. Some evidence suggests that
the hexosamine biosynthesis pathway serves a regulatory
function for glucose uptake by cells7. Thus, a flux of ex-
cess substance into the hexosamine pathway due to the
routing of incoming glucose or glucosamine through the
hexosamine pathway, and/or intracellular accumulation of
glucosamine metabolites, has been suggested to cause
insulin resistance9. Many studies have shown that this
causes impairments in insulin stimulation of glycogen syn-
thase, thereby limiting the flux of glucose in glycogen7,10.
These studies suggest that glucosamine supplementation
could cause glucose intolerance and insulin resistance.
One human intervention trial noted that acute glucosamine
infusion recapitulates some metabolic features of human
diabetes11.
Most of the studies mentioned above, have infused large
amounts of glucosamine into cultured cells, or intra-
venously into rodents in short periods of time. This makes it
difficult to extrapolate the data to the effects of normal
recommended dosages of glucosamine in humans.
As reviewed by Rovanti et al.12, many studies refute the
hypothesis that glucosamine administration causes insulin
resistance. Oral administration to dogs of twice the product
label recommended amounts of glucosamine was reported
to have no effect on fasting blood sugar13. Furthermore,
studies that have investigated the effects of intravenous
glucosamine administration in rodents found that glucose
metabolism is not impaired by short-term glucosamine
supplementation12,14,15.
Currently, there is no conclusive evidence as to the effect
of normal, recommended dosages of glucosamine supple-
mentation on healthy adults’ glucose metabolism, suggest-
ing the need for human intervention trials with glucosamine
aimed at measuring fasting insulin and fasting glucose
levels. No studies to date have investigated the long-term
effects of over-the-counter dosages of glucosamine sulfate
in humans. The closest efforts were reported in two recent
reports. An increase in fasting-insulin levels in a group of
six human subjects orally administered 1500 mg glucosa-
mine sulfate for 12 weeks found no corresponding increase
in glucose, the diagnostic definition of diabetes16. Pouwels
et al. used an euglycemic hyperinsulinemic clamp and
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infused glucosamine sulfate into healthy humans. Pouwel
et al. concluded that glucosamine had no effect on insulin-
induced glucose uptake15. These studies used a small
number of patients, larger dosages of glucosamine than
recommended in humans, and/or administered glucosa-
mine intravenously, which results in an immediate surge
of glucosamine in the blood stream. The experimental
methods used in these two studies make it difficult to
extrapolate directly to what is happening in the bodies of
humans taking normal recommended oral doses of glu-
cosamine supplementation. To date, there is insufficient
evidence in the literature to determine whether the admin-
istration of normal, recommended doses of glucosamine
sulfate as a dietary supplement has any detrimental effects
on the glucose homeostasis of healthy adults. This study
was the first to investigate the effect of supplementation
with 1500 mg of glucosamine sulphate, for 12 weeks in
healthy adults. We tested the hypothesis that glucose
intolerance or insulin resistance does not occur when
normal, recommended doses of glucosamine sulfate are
consumed by healthy adults. We examined the serum
insulin and plasma glucose responses in a group of healthy
adults before, during and after supplementation with glu-
cosamine sulfate. The subjects did not take glucosamine
supplements prior to the study and daily activities and diets
were maintained throughout the study.
Methods
SUBJECT SELECTION
Healthy, non-obese adults were recruited and screened
for health problems including diabetes, other major health
conditions, medication use, supplement use, caffeine
intake, food allergies, smoking, alcohol abuse, drug use,
pregnancy, exercise levels, body mass index (BMI) and
weight changes greater than 10 lbs in the past 6 months.
Subjects were excluded who had a BMI less than 18 or
greater than 32, took supplements or medications that may
interfere with glucose metabolism, had taken glucosamine
in the last 6 months, had diabetes or were allergic to
shellfish. Of the 20 subjects that began the study, one left
for reasons unrelated to the supplementation. All statistics
contain data of only those subjects who completed the
study (N=19). The ages of the subjects in the study ranged
between 22 and 58 years old (mean age=37.7) and the
mean BMI was 25.5 (range 18.6–31.1). See Table I for
subject characteristics. All subjects received both written
and verbal explanation of the study, which received ethics
approval from the University of Guelph Research Ethics
Board. Informed consent was obtained from all subjects.
EXPERIMENT PROTOCOL
This study was a double-blinded, placebo controlled,
human supplementation trial. Subjects were randomized
by age and gender into two groups: placebo (dextrose),
or supplement (glucosamine sulfate). The glucosamine
sulfate (donated by Puresource Inc., Guelph, ON) was
analysed to be 99% pure. Dosages of 500 mg were taken
three times a day, for a 12-week period. Subjects were
instructed to maintain their regular daily physical and medi-
cal activities for the duration of the trial. At baseline, after
an overnight fast, an oral glucose tolerance test (OGTT)
was performed to measure glucose tolerance. This was
repeated at weeks 6 and 12. A catheter was inserted into
the antecubital vein and kept open with 0.9% sodium
chloride solution. Baseline samples of blood were taken
(−15 min, 0 min) into blood collection tubes as previously
indicated. A 10 oz dextrose solution containing 75 g of
glucose was consumed less than 2 min after baseline
samples were taken. Blood samples were then taken at 15,
30, 45, 60, 90, 120, 150 and 180 min post consumption
of the dextrose solution into tubes containing nothing
(for serum) or sodium heparin (for plasma). Subjects
remained seated for the majority of the procedure either
watching a video, conversing or reading. Adherence to the
regimen of tablets was monitored by measuring pill counts
in 6-week intervals and using a questionnaire at the end of
the study.
ANALYSIS
For insulin analysis, non-treated blood was allowed to
clot for at least 30 min and then centrifuged at 2400 rpm for
10 min. Serum was removed and stored at −20°C for
insulin analysis (‘Coat-a-count’ RIA kit, Diagnostic Products
Corporation, Los Angeles, California). Glycated hemo-
globin was analyzed at weeks 0, 6 and 12, as an indicator
of 2–3 month glucose metabolism, using an affinity chroma-
tography column (Glycated Hemoglobin Kit, Sigma
Diagnostics, St. Louis, MO). For glucose analysis, blood
was collected in sodium heparin tubes and 200 µl was
transferred to 1 ml of 0.6 M PCA. Following centrifugation,
the supernatant was stored at −20°C until blood glucose
analysis17.
STATISTICAL ANALYSIS
Serum insulin and plasma glucose for each subject and
OGTT were converted to an area under the curve (AUC)
using the trapezoid method. The resulting AUC data was
analyzed for differences between the supplement and
placebo, as well as across age and gender, using a
repeated measures analysis of variance (SAS 1998). Stat-
istical analysis of glycated hemoglobin values were also
done using a repeated measures analysis of variance.
Differences were accepted as statistically significant if
P<0.05.
Results
SERUM INSULIN
Fig. 1 summarizes the serum insulin data. There were no
significant differences in fasting serum insulin (−15 min and
0 min) between treatments across trials (P=0.99), (Table II).
There were no time (P=0.09) or treatment (P=0.39) effects
between 15 min and 180 min. There were no significant
interactions between treatment and age over-time or
between treatment and gender over-time for insulin. The
insulin levels rose after ingestion of dextrose, but at no
Table I
Physical characteristics of subjects in both treatment groups,
reported as mean with standard deviations when appropriate
Characteristic Placebo (N=8) Glucosamine (N=11)
Females (n) 4 7
Males (n) 4 4
Age (year) 40.3±15 35.9±14
BMI (kg/m2) 24.3±4.3 26.5±4.0
Compliance 0.94±0.08 0.91±0.07
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point in time was there a treatment effect. These values
were not significantly different.
PLASMA GLUCOSE
Fig. 2 summarizes the plasma glucose data. There were
no significant differences in fasting plasma glucose
(−15 min and 0 min) between treatments across trials
(P=0.94), (Table III). Over time, there was a significant
difference (P=0.02) across both groups. There were no
treatment (P=0.4) effects between 15 min and 180 min.
There were no significant interactions between treatment
and age over-time or between treatment and gender over-
time for glucose. The plasma glucose levels rose accord-
ingly after ingestion of dextrose, but at no point in time was
there a treatment effect. These values were not significantly
different.
GLYCATED HEMOGLOBIN
Fig. 3 summarizes the glycated hemoglobin data. There
were no significant changes in glycated hemoglobin levels
between treatments, and across time (P<0.80). There were
no significant differences in glycated hemoglobin levels
between treatment and age (P<0.39) over-time, or between
treatment and gender (P<0.37) over-time.
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Fig. 1. Serum insulin response before and during an OGTT. A represents the placebo treatment group, while B represents the treatment
group receiving glucosamine. Ingestion of dextrose occurred just after time 0. (A) Illustrates mean insulin values for each group during an
OGTT in week 0. (B) Illustrates mean insulin values for each group during an OGTT in week 12. (C) Illustrates mean AUC for insulin.
Table II
Fasting serum insulin (uIU/ml) for both groups, for all three trials.
Values are reported as mean with standard deviations
Treatment Week 0 Week 6 Week 12
Placebo 4.68±1.4 3.38±2.6 6.8±3.4
Glucosamine 5.69±1.7 4.96±4.7 7.7±3.8
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Discussion
As glucosamine supplements become more popular,
there will be increased concern of their safety, in particu-
lar, whether glucosamine supplementation plays a role in
insulin resistance. This study examined whether glucose
intolerance occurs when normal, recommended dosages of
glucosamine sulfate are consumed by healthy adults. The
hexosamine pathway appears to have a regulatory role
in human glucose homeostasis18. An increased flux of
fructose-6-phosphate into the hexosamine pathway has
been shown to cause insulin resistance9. Since glucosa-
mine is metabolized through the hexosamine pathway,
increasing dietary intake of glucosamine sulfate is hypoth-
esized to over-load the system. Studies have shown that
over-loading the hexosamine pathway inhibits basal and
insulin stimulated glucose transport7. Some animal and cell
culture data has shown that glucosamine could cause
insulin resistance by inhibiting glucose transport5–7. Human
studies have not agreed15.
Of note, glucosamine may impair insulin secretion by
causing apoptosis of the insulin secreting beta cells19. This
may be caused by beta cells having a high affinity for
glucosamine transporters. This apoptosis may inhibit
insulin secretion thereby blunting a compensatory insulin
response to the induction of insulin making it appear that
glucosamine does not cause insulin resistance, when it
may in fact do so. Detection methods of this study and the
use of non-diabetic patients limit the ability of this study to
determine if this process occurred. The data, however, add
to the growing number of publications investigating the
effect of glucosamine on glucose tolerance.
Results of this study suggest that there was no difference
between placebo and treatment groups in terms of
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Fig. 2. Plasma glucose response before and during an OGTT, for both placebo and glucosamine groups. Ingestion of dextrose occurred just
after time 0. (A) Illustrates mean glucose values for each group during an OGTT in week 0. (B) Illustrates mean glucose values for each
group during an OGTT in week 12. (C) Illustrates mean AUC for glucose.
Table III
Fasting plasma glucose (mmol/l) both groups, for all three trials.
Values are reported as means with standard deviations
Treatment Week 0 Week 6 Week 12
Placebo 4.24±0.73 4.52±0.65 4.47±0.84
Glucosamine 4.57±0.55 3.85±0.20 4.40±0.63
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circulating insulin or glucose prior to the ingestion of the
dextrose drink of the first OGTT, nor prior to dextrose
ingestion in any of the subsequent trials. Furthermore, no
significant differences within or between treatments in
these measures in the succeeding 3-h post-ingestion
period of the OGTT was found. As results of the OGTT
showed no significant change, then insulin resistance was
most likely also not significantly changed. Although this
data suggests that the use of normal, recommended doses
of glucosamine sulfate does not cause glucose intolerance
or insulin resistance in healthy adults, the small number of
subjects and the large standard deviations which occurred
in this study mean that we cannot conclusively determine
this and results from future studies are needed.
A lack of change in levels of glycated hemogloblin, a
measure of 2–3 month glucose metabolism, supports our
hypothesis that chronic administration of normal, recom-
mended doses of glucosamine sulfate does cause large
alterations in glucose metabolism in healthy adults. Fur-
thermore, the lack of alteration in insulin levels in associ-
ation with glucosamine sulfate administration observed in
this study, might suggest that this procedure did not admin-
ister sufficient glucosamine to overload the hexosamine
pathway. Again definitive conclusions must await the
results of future trials using larger subject pools and
different methodologies.
These findings are difficult to compare to other studies as
most previous research has involved the administration
of large amounts of glucosamine in short periods of time
into cultured cells or intravenously to rodents6,20. These
studies cannot be extrapolated to humans supplemented
orally with normal recommended dosages of glucosamine.
There have been two human studies in which healthy
adults were supplemented with glucosamine. The first
noted an increase in fasting-insulin levels without a corre-
sponding increase in glucose16, suggesting insulin resist-
ance. These results differ from this study. This may be
due to subjects used, and/or other variables such as the
different methods used to measure insulin sensitivity. The
second was noted in a recently published letter in Diabetes
Care by Yu et al.21 concerning a study that was similar to
this one. They found no difference between placebo
and supplemented groups after 6 weeks of glucosamine
treatment.
This study does not provide a definitive conclusion to the
debate surrounding the issue of glucosamine supplemen-
tation and insulin resistance. Limitations to this study
include the small number of subjects and the short duration
period. Also, the use of insulin and glucose levels to detect
changes in insulin sensitivity is a surrogate approach to
measure insulin action and is not the gold standard for
measuring insulin sensitivity. A euglycemic insulin clamp
technique would be a superior method to measure insulin
sensitivity in future studies. Future studies should investi-
gate the effects of longer periods of glucosamine sulfate
supplementation, ideally up to 2 years, to determine the
effects on glucose metabolism in prolonged users, such as
osteoarthritis patients. Also, higher dosages of glucosa-
mine sulfate should be tested, to take into consideration
users who take more than the recommended dosage. Most
importantly, future studies should investigate subject
groups with more sensitive glucose metabolism such as the
elderly and diabetics. This may shed light on the extent of
any potential alterations in glucose metabolism caused by
glucosamine supplementation. Measurement of secondary
indicators of metabolism including C-peptide and serum
glycerol may also be useful in future studies.
In summary, this investigation of 12 weeks of supplemen-
tation with 1500 mg of glucosamine sulfate in healthy
adults, the dose most often recommended to osteoarthritis
patients, suggests that changes in glucose homeostasis
does not occur. Definitive conclusions await more studies in
this area.
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